Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Up 77.4% in December

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 168,900 shares, an increase of 77.4% from the November 30th total of 95,200 shares. Based on an average daily volume of 3,180,000 shares, the short-interest ratio is presently 0.1 days.

Quoin Pharmaceuticals Stock Performance

Shares of NASDAQ:QNRX traded down $0.01 during midday trading on Friday, reaching $0.55. The company’s stock had a trading volume of 553,804 shares, compared to its average volume of 1,118,553. The firm has a 50 day moving average price of $0.68 and a two-hundred day moving average price of $0.63. Quoin Pharmaceuticals has a fifty-two week low of $0.43 and a fifty-two week high of $6.18. The firm has a market capitalization of $2.78 million, a price-to-earnings ratio of -0.14 and a beta of 1.79.

Insider Activity

In other news, CFO Gordon Dunn purchased 122,221 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were purchased at an average cost of $0.45 per share, with a total value of $54,999.45. Following the completion of the purchase, the chief financial officer now owns 151,077 shares of the company’s stock, valued at $67,984.65. This trade represents a 423.55 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, COO Denise P. Carter purchased 555,556 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was acquired at an average price of $0.45 per share, with a total value of $250,000.20. Following the completion of the transaction, the chief operating officer now owns 602,648 shares in the company, valued at approximately $271,191.60. This trade represents a 1,179.72 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 777,777 shares of company stock worth $350,000. Corporate insiders own 3.70% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.